File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Impact of radiofrequency ablation on the management of patients with hepatocellular carcinoma in a specialized centre

TitleImpact of radiofrequency ablation on the management of patients with hepatocellular carcinoma in a specialized centre
Authors
Issue Date2004
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.bjs.co.uk
Citation
British Journal Of Surgery, 2004, v. 91 n. 3, p. 334-338 How to Cite?
AbstractBackground: Radiofrequency ablation (RFA) has been used increasingly in the treatment of hepatocellular carcinoma (HCC). The aim of this study was to investigate changes in the treatment pattern of primary HCC following the implementation of RFA in a specialized surgical centre. Methods: This was a retrospective analysis of all 894 patients admitted for treatment of primary HCC over 36 months. Results: There was no difference in the age, sex ratio, liver function according to Child-Pugh grade, serum α-fetoprotein concentration, hepatitis B surface antigen status and tumour size among patients before and after the introduction of RFA therapy. Fifty-one patients (10.6 per cent) with primary HCC received RFA treatment after its implementation. There was a 6.8 per cent reduction in the number of patients who had supportive treatment (P = 0.041) and a 3.2 per cent reduction in surgical treatment. The hospital mortality rates for RFA and surgery were 2.0 and 4.9 per cent respectively. The overall survival rates at 6, 12 and 18 months for patients treated with RFA were 92.2, 73.4 and 61.2 per cent respectively. The corresponding survival rates for the 213 patients who had surgery were 88.0, 77.0 and 71.5 per cent. These values were no different from those in patients who had RFA (P = 0.718). Patients treated with RFA or surgery survived longer than those who had other treatments. Conclusion: RFA had a significant impact on the management of primary HCC, increasing the number of patients suitable for liver-directed therapy and leading to survival benefit. RFA may become the treatment of choice for patients with irresectable HCC.
Persistent Identifierhttp://hdl.handle.net/10722/84011
ISSN
2015 Impact Factor: 5.596
2015 SCImago Journal Rankings: 2.966
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, CMen_HK
dc.contributor.authorNg, KKCen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorAi, Ven_HK
dc.contributor.authorYuen, Jen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T08:47:52Z-
dc.date.available2010-09-06T08:47:52Z-
dc.date.issued2004en_HK
dc.identifier.citationBritish Journal Of Surgery, 2004, v. 91 n. 3, p. 334-338en_HK
dc.identifier.issn0007-1323en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84011-
dc.description.abstractBackground: Radiofrequency ablation (RFA) has been used increasingly in the treatment of hepatocellular carcinoma (HCC). The aim of this study was to investigate changes in the treatment pattern of primary HCC following the implementation of RFA in a specialized surgical centre. Methods: This was a retrospective analysis of all 894 patients admitted for treatment of primary HCC over 36 months. Results: There was no difference in the age, sex ratio, liver function according to Child-Pugh grade, serum α-fetoprotein concentration, hepatitis B surface antigen status and tumour size among patients before and after the introduction of RFA therapy. Fifty-one patients (10.6 per cent) with primary HCC received RFA treatment after its implementation. There was a 6.8 per cent reduction in the number of patients who had supportive treatment (P = 0.041) and a 3.2 per cent reduction in surgical treatment. The hospital mortality rates for RFA and surgery were 2.0 and 4.9 per cent respectively. The overall survival rates at 6, 12 and 18 months for patients treated with RFA were 92.2, 73.4 and 61.2 per cent respectively. The corresponding survival rates for the 213 patients who had surgery were 88.0, 77.0 and 71.5 per cent. These values were no different from those in patients who had RFA (P = 0.718). Patients treated with RFA or surgery survived longer than those who had other treatments. Conclusion: RFA had a significant impact on the management of primary HCC, increasing the number of patients suitable for liver-directed therapy and leading to survival benefit. RFA may become the treatment of choice for patients with irresectable HCC.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.bjs.co.uken_HK
dc.relation.ispartofBritish Journal of Surgeryen_HK
dc.rightsBritish Journal of Surgery. Copyright © John Wiley & Sons Ltd.en_HK
dc.titleImpact of radiofrequency ablation on the management of patients with hepatocellular carcinoma in a specialized centreen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0007-1323&volume=91&issue=3&spage=334&epage=338&date=2004&atitle=Impact+of+radiofrequency+ablation+on+the+management+of+patients+with+hepatocellular+carcinoma+in+a+specialized+centreen_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/bjs.4448en_HK
dc.identifier.pmid14991635-
dc.identifier.scopuseid_2-s2.0-1642355178en_HK
dc.identifier.hkuros87691en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1642355178&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume91en_HK
dc.identifier.issue3en_HK
dc.identifier.spage334en_HK
dc.identifier.epage338en_HK
dc.identifier.isiWOS:000220667000014-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLam, CM=7402989820en_HK
dc.identifier.scopusauthoridNg, KKC=7403179075en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridAi, V=6603342063en_HK
dc.identifier.scopusauthoridYuen, J=7102620431en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats